1. Clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-d ethylidene gluocoside (NSC 141540) VP-16-213;Falkson,1974
2. Second trial drugs in ovarian cancer;Stanhope;Gynecol. Oncol.,1977
3. Phase I clinical trial of a new antitumor agent, 4′-demethylepipodophyllotoxin 9-(4,6-0 ethylidene-β-d-glucopyranoside) (NSC-141540; VP-16-213);Nissen;Cancer Chemother. Rep.,1972
4. Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer;Eagan;Oncology,1976
5. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer;Ahmann;Cncer Treat. Rep.,1976